Taurine protects against myelin damage of sciatic nerve in diabetic peripheral neuropathy rats by controlling apoptosis of schwann cells via NGF/Akt/GSK3β pathway

Exp Cell Res. 2019 Oct 15;383(2):111557. doi: 10.1016/j.yexcr.2019.111557. Epub 2019 Aug 12.

Abstract

Diabetic peripheral neuropathy is a common complications of Type 2 Diabetes and its main pathological feature is myelin sheath damage of peripheral nerve that was induced by Schwann cells (SCs) apoptosis. Increasing evidence suggested that taurine might play a role in improving DPN because of its ability to prevent SCs apoptosis. In this study, we explore the effect of taurine on preventing SCs apoptosis and its underlying mechanism. Sprague Dawley rats were treated with streptozotocin to establish the diabetes model. Rats were randomly divided into control, diabetes, taurine treatment (as giving 0.5%, 1% and 2% taurine in drinking water) groups. RSC96 cell (a rat SCs line) was used for intervention experiments in vitro. Results showed that taurine significantly corrected morphology of damaged myelin sheath and inhibited SCs apoptosis in sciatic nerve of diabetic rats. Moreover, taurine prevented apoptosis of RSC96 cells exposed to high glucose. Mechanistically, taurine up-regulated NGF expression and phosphorylation levels of Akt and GSK3β, while, blocking activation of NGF and phosphorylation of Akt and GSK3β increased apoptosis of high glucose-exposed RSC96 cells with taurine supplement. These results revealed taurine improved the myelin sheath damage of sciatic nerve in diabetic rats by controlling SCs apoptosis via NGF/Akt/GSK3β signaling pathways, which provides some clues that taurine might be effective and feasible candidate for the treatment of DPN.

Keywords: Apoptosis; Diabetic peripheral neuropathy; NGF/Akt/GSK3β pathway; Schwann cells; Taurine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / drug effects*
  • Demyelinating Diseases / pathology
  • Demyelinating Diseases / prevention & control
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / pathology
  • Diabetic Neuropathies / drug therapy
  • Diabetic Neuropathies / etiology
  • Diabetic Neuropathies / pathology*
  • Glycogen Synthase Kinase 3 beta / metabolism
  • Male
  • Myelin Sheath / drug effects*
  • Myelin Sheath / pathology
  • Nerve Growth Factor / metabolism
  • Protective Agents / pharmacology*
  • Protective Agents / therapeutic use
  • Proto-Oncogene Proteins c-akt / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Schwann Cells / drug effects*
  • Schwann Cells / physiology
  • Sciatic Nerve / drug effects*
  • Sciatic Nerve / pathology
  • Signal Transduction / drug effects
  • Streptozocin
  • Taurine / pharmacology*
  • Taurine / therapeutic use

Substances

  • Protective Agents
  • Taurine
  • Streptozocin
  • Nerve Growth Factor
  • Glycogen Synthase Kinase 3 beta
  • Proto-Oncogene Proteins c-akt